TABLE 1.
Baseline characteristics at time of initiation of AMK inhalation therapya
| Clinical characteristics | Value(s) |
|---|---|
| Median (IQR) age (yr) | 60 (53–69) |
| No. (%) of female patients | 53 (69) |
| Median (IQR) body mass index (kg/m2) | 19.8 (18.1–21.8) |
| No. (%) of nonsmokers | 60 (78) |
| No. (%) of patients with the following underlying lung disease: | |
| Previous pulmonary tuberculosis | 57 (74) |
| Chronic cavitary pulmonary aspergillosis | 17 (22) |
| Chronic obstructive pulmonary disease | 9 (12) |
| No. (%) of patients in whom the etiologic organism was: | |
| M. abscessus complex | 48 (62) |
| M. abscessus | 35 |
| M. massiliense | 12 |
| M. bolletii | 1 |
| M. avium complex | 20 (26) |
| M. intracellulare | 14 |
| M. avium | 6 |
| Mixture of bacteria | 9 (12) |
| No. (%) of patients with the following radiological findings: | |
| Nodular bronchiectatic form | 47 (61) |
| With cavity | 25 |
| Without cavity | 22 |
| Fibrocavitary form | 30 (39) |
| Laboratory findings | |
| No. (%) of patients with acid-fast bacillus smear-positive sputum | 51 (66) |
| Median (IQR) albumin concn (g/dl) | 3.8 (3.5–4.1) |
| Median (IQR) C-reactive protein concn (mg/dl) | 1.4 (0.4–3.6) |
| Median (IQR) erythrocyte sedimentation rate (mm/h) | 49 (34–90) |
| Median (IQR) forced expiratory vol in 1 s (%) | 63 (46–75) |
| No. (%) of patients whose isolates had: | |
| Macrolide resistance | 63 (82) |
| Amikacin resistance | 5 (7) |
a
Data are for a total of 77 patients. Abbreviations: AMK, amikacin; IQR, interquartile range.